BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34531523)

  • 1. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
    Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
    Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.
    Kapur P; Gao M; Zhong H; Chintalapati S; Mitui M; Barnes SD; Zhou Q; Miyata J; Carrillo D; Malladi VS; Rakheja D; Pedrosa I; Xu L; Kinch L; Brugarolas J
    Mod Pathol; 2022 Mar; 35(3):333-343. PubMed ID: 34538873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
    Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
    Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
    Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
    Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations.
    Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
    Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
    [No Abstract]   [Full Text] [Related]  

  • 6. Concordance of MTOR Pathway Mutations and the Diagnosis of Renal Low-Grade Oncocytic Tumor (LOT).
    Siegmund SE; Al-Obaidy KI; Tsai HK; Idrees MT; Akgul M; Acosta AM; Hirsch MS
    Int J Surg Pathol; 2024 Apr; 32(2):316-330. PubMed ID: 37357748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological features of low-grade oncocytic renal tumor (CD117-negative, cytokeratin 7-positive): report of seven cases].
    Xie B; Cheng LC; Yin GL; Liu BA; Hu ZL; Tong K
    Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):719-725. PubMed ID: 35922161
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
    Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
    Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
    Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
    Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low grade oncocytic renal tumor (LOT): Clinicopathological characterization of 13 cases.
    Almutairi F; Xu B
    Pathol Res Pract; 2024 Feb; 254():155127. PubMed ID: 38241777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
    Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
    Mansoor M; Siadat F; Trpkov K
    Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
    Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
    Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CK7+/CD117- low grade oncocytic tumor of the kidney: a clinicopathological analysis].
    Bai YF; Chang CD; Wang B; Zhao M; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):976-980. PubMed ID: 36207909
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-Grade Oncocytic Tumor: Report of Two Cases of An Emerging Entity in the Spectrum of Oncocytic Renal Neoplasms.
    Sharma D; Pai T; Prakash G; Desai S; Menon S
    Turk Patoloji Derg; 2022; 38(2):162-166. PubMed ID: 34514579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics.
    Kravtsov O; Gupta S; Cheville JC; Sukov WR; Rowsey R; Herrera-Hernandez LP; Lohse CM; Knudson R; Leibovich BC; Jimenez RE
    Hum Pathol; 2021 Aug; 114():9-18. PubMed ID: 33961838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
    Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
    Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China.
    Guo Q; Liu N; Wang F; Guo Y; Yang B; Cao Z; Wang Y; Wang Y; Zhang W; Huang Q; Zhao W; Liu C; Qu T; Li L; Cao L; Ren D; Meng B; Qi L; Wang C; Cao W
    Virchows Arch; 2021 Mar; 478(3):449-458. PubMed ID: 32918598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.